Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Dura

Authors

Tanya Siddiqi (ORCID: https://orcid.org/0000-0001-5292-8298)
Susan O’Brien (ORCID: https://orcid.org/0000-0002-2481-7504)
Dennis A. Carney (ORCID: https://orcid.org/0000-0003-3239-6065)
Alessandra Tedeschi (ORCID: https://orcid.org/0000-0001-8724-2771)
John Nathan Allan (ORCID: https://orcid.org/0000-0002-2088-0899)
Constantine Si Lun Tam (ORCID: https://orcid.org/0000-0002-9759-5017)
Thomas J. Kipps (ORCID: https://orcid.org/0000-0002-0064-4549)
Andrea Visentin (ORCID: https://orcid.org/0000-0003-0271-7200)
Lynne Neumayr (ORCID: https://orcid.org/0000-0003-1579-5865)
Cathy Zhou (ORCID: https://orcid.org/0000-0003-2406-1484)
Paul M. Barr (ORCID: https://orcid.org/0000-0002-9733-401X)
Jutta K. Neuenburg
Javier de la Serna (ORCID: https://orcid.org/0000-0003-3904-1101)
Masa Lasica (ORCID: https://orcid.org/0000-0001-7971-4003)
Xavier C. Badoux (ORCID: https://orcid.org/0000-0001-9042-527X)
Paolo Ghia (ORCID: https://orcid.org/0000-0003-3750-7342)
Anita Szoke (ORCID: https://orcid.org/0000-0001-6975-7114)
James P. Dean (ORCID: https://orcid.org/0000-0001-8058-1682)
William G. Wierda
Ryan Jacobs
Edith Szafer Glusman
Anna Elinder Cambrun

Institutions

City Of Hope National Medical Center (US)
The University of Texas MD Anderson Cancer Center (US)
University of Padua (IT)
Vita-Salute San Raffaele University (IT)
University of California, Irvine (US)
Cornell University (US)
Peter MacCallum Cancer Centre (AU)
North Shore Hospital (NZ)
University of Rochester Medical Center (US)
AbbVie (United States) (US)
St Vincent's Hospital Melbourne (AU)
Levine Cancer Institute (US)
Hospital Universitario 12 De Octubre (ES)
IRCCS Ospedale San Raffaele (IT)
Community Cancer Center (US)
Weill Cornell Medicine (US)
Monash University (AU)

Publication Details

Journal: Blood
Published: 2024-11-05
DOI: https://doi.org/10.1182/blood-2024-200936
Citations: 4
Primary Topic: Chronic Lymphocytic Leukemia Research
Type: article
Field-Weighted Citation Impact: 1.75

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Dura

Tanya Siddiqi, Susan O’Brien, Dennis A. Carney, Alessandra Tedeschi, John Nathan Allan, Constantine Si Lun Tam, Thomas J. Kipps, Andrea Visentin, Lynne Neumayr, Cathy Zhou, Paul M. Barr, Jutta K. Neuenburg, Javier de la Serna, Masa Lasica, Xavier C. Badoux, Paolo Ghia, Anita Szoke, James P. Dean, William G. Wierda, Ryan Jacobs, Edith Szafer Glusman, Anna Elinder Cambrun

November 5, 2024article en

4 citations

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Dura

Authors

Institutions

Publication Details

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Dura

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Dura

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.